Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | -0.86% | -5.45% | -15.98% |
Jul. 01 | Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell 3000E Index | CI |
Jul. 01 | Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Microcap Index | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.98% | 63.72M | C | ||
+18.97% | 45.34B | B- | ||
+41.98% | 40.42B | A | ||
-10.06% | 37.92B | B | ||
+31.15% | 31.75B | B | ||
-7.79% | 27.71B | C | ||
+13.32% | 26.52B | B- | ||
+43.05% | 13.96B | B+ | ||
+31.28% | 12.44B | C+ | ||
-7.41% | 11.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DTIL Stock
- Ratings Precision BioSciences, Inc.